Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study

SIMPLE SUMMARY: We evaluated the efficacy and safety of molecular-targeted therapies (MTTs) in 29 patients who discontinued the combination therapy of nivolumab plus ipilimumab (NIVO+IPI) for advanced or metastatic renal cell carcinoma as real-world outcomes. Patients receiving MTTs had a median fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Iinuma, Koji, Kameyama, Koji, Taniguchi, Tomoki, Kawada, Kei, Ishida, Takashi, Takagi, Kimiaki, Nagai, Shingo, Enomoto, Torai, Tomioka, Masayuki, Kawase, Makoto, Takeuchi, Shinichi, Kato, Daiki, Takai, Manabu, Nakane, Keita, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559555/
https://www.ncbi.nlm.nih.gov/pubmed/36230501
http://dx.doi.org/10.3390/cancers14194579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559555/
https://www.ncbi.nlm.nih.gov/pubmed/36230501
http://dx.doi.org/10.3390/cancers14194579

Ejemplares similares